Pierre Fabre and Lonza Enter Manufacturing Agreement

Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, and French pharmaceutical group Pierre Fabre, have entered into a manufacturing agreement.

This collaboration is aimed at manufacturing W0180, an innovative monoclonal antibody discovered by Pierre Fabre targeting the VISTA checkpoint, currently being investigated as a single agent and in combination with pembrolizumab in a Phase I clinical trial (NCT04564417) in various solid tumors.

Lonza will provide cGMP drug product (DP) manufacturing services for clinical supply from its fill-finish facility at Stein, Switzerland.

“We are delighted to entrust the production of the W0180 drug product to Lonza,” said Jean-Luc Lowinski, CEO, Pierre Fabre Medical Care. “Its drug product services are well-suited for our innovative therapy manufacturing needs. The W0180 will be manufactured in Lonza’s GS Xceed Expression CHO System, also successfully used for the IGF1R and cMet antibodies discovered by Pierre Fabre.”